Cancer Biomarkers Market by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma), Product (Instruments, Consumables), Application (Diagnostics, R&D), End User (Diagnostic Laboratories), And Region - Global Forecast to 2032

1 INTRODUCTION 37 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 40 1.3 STUDY SCOPE 41 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 41 1.3.2 INCLUSIONS AND EXCLUSIONS 42 1.3.3 YEARS CONSIDERED 43 1.4 CURRENCY CONSIDERED 43 1.5 STAKEHOLDERS 43 1.6 SUMMARY OF CHANGES 44 2 EXECUTIVE SUMMARY 45 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 45 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 46 2.3 DISRUPTIVE TRENDS SHAPING MARKET 47 2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 48 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49 3 PREMIUM INSIGHTS 50 3.1 CANCER BIOMARKERS MARKET OVERVIEW 50 3.2 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY 51 3.3 CANCER BIOMARKERS MARKET, BY CANCER TYPE 51 3.4 CANCER BIOMARKERS MARKET, BY PRODUCT 52 3.5 CANCER BIOMARKERS MARKET, BY APPLICATION 52 3.6 CANCER BIOMARKERS MARKET, BY END USER 53 3.7 CANCER BIOMARKERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 4 MARKET OVERVIEW 54 4.1 INTRODUCTION 54 4.2 MARKET DYNAMICS 55 4.2.1 DRIVERS 55 4.2.1.1 Technological Advancements in Cancer Biomarkers 55 4.2.1.2 Increasing incidence of cancer 56 4.2.1.3 Growing adoption of cancer biomarkers in drug discovery and development 58 4.2.1.4 Increasing investments in research and development for biomarker innovation 59 4.2.1.5 Growing Adoption of Non-Invasive Diagnostics (Liquid Biopsy) 59 4.2.1.6 Supportive Government Initiatives and Cancer Awareness Programs 60 4.2.2 RESTRAINTS 61 4.2.2.1 High capital requirements and long development timelines for biomarker commercialization 61 4.2.2.2 Unfavorable regulatory frameworks and reimbursement limitations 62 4.2.2.3 High Cost of Biomarker-Based Diagnostic Tests 62 4.2.3 OPPORTUNITIES 63 4.2.3.1 Expanding role of personalized and precision medicine 63 4.2.3.2 Increasing applications of companion diagnostics in oncology 63 4.2.3.3 Growth potential in emerging economies 64 4.2.3.4 Integration of AI and Multi-Omics Approaches in Biomarker Discovery and Analysis 65 4.2.4 CHALLENGES 65 4.2.4.1 Technical challenges related to sample collection, handling, and storage 65 4.2.4.2 Complexities associated with biomarker validation and standardization 66 4.2.4.3 Shortage of skilled professionals and technical expertise 67 4.3 UNMET NEEDS AND WHITE SPACES 67 4.3.1 UNMET NEEDS IN CANCER BIOMARKERS MARKET 67 4.3.2 WHITE SPACE OPPORTUNITIES 68 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 69 4.4.1 INTERCONNECTED MARKETS 69 4.4.2 CROSS-SECTOR OPPORTUNITIES 70 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 71 4.5.1 KEY MOVES AND STRATEGIC FOCUS 71 5 INDUSTRY TRENDS 72 5.1 PORTER’S FIVE FORCES ANALYSIS 72 5.1.1 THREAT OF NEW ENTRANTS 73 5.1.2 THREAT OF SUBSTITUTES 73 5.1.3 BARGAINING POWER OF BUYERS 73 5.1.4 BARGAINING POWER OF SUPPLIERS 73 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 74 5.2 MACROECONOMIC INDICATORS 74 5.2.1 SINTRODUCTION 74 5.2.2 GDP TRENDS AND FORECAST 74 5.3 SUPPLY CHAIN ANALYSIS 77 5.4 VALUE CHAIN ANALYSIS 78 5.5 ECOSYSTEM ANALYSIS 80 5.6 PRICING ANALYSIS 81 5.6.1 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024–2026 81 5.6.2 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026 82 5.7 TRADE ANALYSIS 83 5.7.1 IMPORT SCENARIO (HS CODE 382200) 83 5.7.2 EXPORT SCENARIO (HS CODE 382200) 83 5.8 KEY CONFERENCES & EVENTS, 2026–2027 84 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 85 5.10 INVESTMENT & FUNDING SCENARIO 86 5.11 IMPACT OF 2025 US TARIFF ON CANCER BIOMARKERS MARKET 86 5.11.1 INTRODUCTION 86 5.11.2 KEY TARIFF RATES 87 5.11.3 PRICE IMPACT ANALYSIS 87 5.11.4 IMPACT ON REGION 88 5.11.4.1 North America 88 5.11.4.2 Europe 88 5.11.4.3 Asia Pacific 88 5.11.5 IMPACT ON END-USE INDUSTRIES 89 5.11.5.1 Diagnostic Laboratories 89 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 90 6.1 KEY EMERGING TECHNOLOGIES 90 6.1.1 NEXT-GENERATION SEQUENCING 90 6.1.2 POLYMERASE CHAIN REACTION 90 6.1.3 IMMUNOASSAYS 91 6.2 COMPLEMENTARY TECHNOLOGIES 91 6.2.1 BIOINFORMATICS PLATFORMS 91 6.2.2 MASS SPECTROMETRY 92 6.3 ADJACENT TECHNOLOGIES 92 6.3.1 LIQUID BIOPSY TECHNOLOGIES 92 6.3.2 MICROARRAY TECHNOLOGIES 93 6.4 TECHNOLOGY/PRODUCT ROADMAP 93 6.5 PATENT ANALYSIS 95 6.5.1 LIST OF KEY PATENTS 96 6.6 FUTURE APPLICATIONS 97 6.7 IMPACT OF AI/GENERATIVE AI ON CANCER BIOMARKERS MARKET 97 6.7.1 INTRODUCTION 97 6.7.2 TOP USE CASES AND MARKET POTENTIAL 98 6.7.3 KEY COMPANIES IMPLEMENTING AI 99 6.7.4 FUTURE OF AI 99   7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 100 7.1 DECISION-MAKING PROCESS 100 7.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 100 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 100 7.2.2 BUYING CRITERIA 101 7.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 102 7.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 103 7.5 MARKET PROFITABILITY 104 7.5.1 REVENUE POTENTIAL 104 7.5.2 COST DYNAMICS 105 7.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 105 8 CANCER BIOMARKERS MARKET, BY TECHNOLOGY 106 8.1 INTRODUCTION 107 8.2 OMICS TECHNOLOGIES 107 8.2.1 PROTEOMICS 110 8.2.1.1 Immunoassays 114 8.2.1.1.1 Facilitate diagnosis of cancer at early stage 114 8.2.1.2 Mass spectrometry 115 8.2.1.2.1 High specificity of mass spectroscopy to drive adoption 115 8.2.1.3 2D gel electrophoresis 116 8.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment 116 8.2.1.4 Protein microarrays 117 8.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth 117 8.2.1.5 Other proteomic technologies 118 8.2.2 GENOMICS 120 8.2.2.1 Next-generation sequencing 123 8.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth 123 8.2.2.2 Polymerase chain reaction 124 8.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market 124 8.2.2.3 In situ hybridization 125 8.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials 125 8.2.3 OTHER OMICS TECHNOLOGIES 126 8.3 IMAGING TECHNOLOGIES 129 8.3.1 ULTRASOUND IMAGING 132 8.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth 132   8.3.2 COMPUTED TOMOGRAPHY 135 8.3.2.1 Technological advancements to drive adoption 135 8.3.3 MAGNETIC RESONANCE IMAGING 138 8.3.3.1 Growing preference for open MRIs to support market growth 138 8.3.4 POSITRON EMISSION TOMOGRAPHY 141 8.3.4.1 Development of lab-on-chip-based multiplex assays to propel market 141 8.3.5 MAMMOGRAPHY 144 8.3.5.1 Advanced technologies like 3D mammography to support market growth 144 9 CANCER BIOMARKERS MARKET, BY CANCER TYPE 148 9.1 INTRODUCTION 149 9.2 BREAST CANCER 150 9.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET 150 9.3 LUNG CANCER 153 9.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH 153 9.4 COLORECTAL CANCER 156 9.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET 156 9.5 PROSTATE CANCER 159 9.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET 159 9.6 MELANOMA 162 9.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET 162 9.7 LEUKEMIA 165 9.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET 165 9.8 THYROID CANCER 168 9.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH 168 9.9 BLADDER CANCER 171 9.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET 171 9.10 NON-HODGKIN’S LYMPHOMA 174 9.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET 174 9.11 KIDNEY CANCER 177 9.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET 177 9.12 OTHER CANCERS 180   10 CANCER BIOMARKERS MARKET, BY PRODUCT 184 10.1 INTRODUCTION 185 10.2 CONSUMABLES 185 10.2.1 KITS & REAGENTS 188 10.2.1.1 Ease of use to support adoption 188 10.2.2 ANTIBODIES 191 10.2.2.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market 191 10.2.3 PROBES 194 10.2.3.1 Need for probes in assay tests for cancer detection to support market growth 194 10.3 INSTRUMENTS 197 10.3.1 IMAGING INSTRUMENTS 200 10.3.1.1 Technological advancements in imaging instruments to drive growth 200 10.3.2 PATHOLOGY-BASED INSTRUMENTS 202 10.3.2.1 Rising demand for cancer diagnosis to drive market 202 10.3.3 BIOPSY INSTRUMENTS 205 10.3.3.1 Increasing prevalence of cancer to drive growth 205 10.4 BIOINFORMATICS SOFTWARE 207 10.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET 207 11 CANCER BIOMARKERS MARKET, BY APPLICATION 211 11.1 INTRODUCTION 212 11.2 DIAGNOSTICS 212 11.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET 212 11.3 RESEARCH & DEVELOPMENT 215 11.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 215 11.4 PROGNOSTICS 218 11.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH 218 11.5 RISK ASSESSMENT 221 11.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS 221 11.6 OTHER APPLICATIONS 224 12 CANCER BIOMARKERS MARKET, BY END USER 228 12.1 INTRODUCTION 229 12.2 DIAGNOSTIC LABORATORIES 229 12.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH 229   12.3 BIOPHARMACEUTICAL COMPANIES AND CROS 232 12.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET 232 12.4 RESEARCH AND ACADEMIC INSTITUTES 235 12.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET 235 12.5 OTHER END USERS 239 13 CANCER BIOMARKERS MARKET, BY REGION 242 13.1 INTRODUCTION 243 13.2 NORTH AMERICA 244 13.2.1 US 251 13.2.1.1 High adoption of precision oncology and biomarker-driven therapies to drive market growth 251 13.2.2 CANADA 257 13.2.2.1 Government Initiatives Driving Biomarker Growth 257 13.3 EUROPE 264 13.3.1 GERMANY 272 13.3.1.1 High Healthcare Spending Driving Biomarker Adoption 272 13.3.2 UK 278 13.3.2.1 Rising Cancer Incidence Driving Biomarker Adoption 278 13.3.3 FRANCE 283 13.3.3.1 Government Funding Supporting Biomarker Market Growth 283 13.3.4 ITALY 288 13.3.4.1 Growing geriatric population to support market growth 288 13.3.5 SPAIN 293 13.3.5.1 Rising emphasis on personalized medicine to drive market growth 293 13.3.6 REST OF EUROPE 298 13.4 ASIA PACIFIC 304 13.4.1 CHINA 311 13.4.1.1 Rising cancer burden and strong government support to drive market growth 311 13.4.2 JAPAN 316 13.4.2.1 Strong healthcare investment to drive market growth 316 13.4.3 INDIA 321 13.4.3.1 Rising cancer burden and expanding healthcare investments to drive market growth 321 13.4.4 AUSTRALIA 326 13.4.4.1 Rising cancer burden and strong government investments to drive market growth 326 13.4.5 REST OF ASIA PACIFIC 331   13.5 LATIN AMERICA 337 13.5.1 BRAZIL 342 13.5.1.1 Rising cancer incidence to drive market growth 342 13.5.2 MEXICO 347 13.5.2.1 Expanding healthcare access and rising cancer burden to drive market growth 347 13.5.3 REST OF LATIN AMERICA 352 13.6 MIDDLE EAST & AFRICA 358 13.6.1 EMERGING PRECISION MEDICINE INITIATIVES TO DRIVE MARKET GROWTH 358 13.7 GCC COUNTRIES 363 13.7.1 EXPANDING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH 363 14 COMPETITIVE LANDSCAPE 369 14.1 INTRODUCTION 369 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 369 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER BIOMARKERS MARKET 369 14.3 REVENUE ANALYSIS, 2023–2025 371 14.4 MARKET SHARE ANALYSIS, 2025 372 14.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 372 14.4.2 US: MARKET SHARE ANALYSIS, 2025 374 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 374 14.5.1 STARS 374 14.5.2 EMERGING LEADERS 375 14.5.3 PERVASIVE PLAYERS 375 14.5.4 PARTICIPANTS 375 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 377 14.5.5.1 Company footprint 377 14.5.5.2 Regional footprint 377 14.5.5.3 Product footprint 378 14.5.5.4 Profiling Technology footprint 379 14.5.5.5 Application footprint 379 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 380 14.6.1 PROGRESSIVE COMPANIES 380 14.6.2 RESPONSIVE COMPANIES 380 14.6.3 DYNAMIC COMPANIES 380 14.6.4 STARTING BLOCKS 380 14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 382 14.6.5.1 Detailed list of key startups/SMEs 382 14.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 382 14.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 383   14.7 COMPANY VALUATION & FINANCIAL METRICS 383 14.7.1 FINANCIAL METRICS 383 14.7.2 COMPANY VALUATION 384 14.8 BRAND/PRODUCT COMPARISON 384 14.9 COMPETITIVE SCENARIO 385 14.9.1 PRODUCT LAUNCHES & APPROVALS 385 14.9.2 DEALS 386 15 COMPANY PROFILES 387 15.1 KEY PLAYERS 387 15.1.1 F. HOFFMANN-LA ROCHE AG 387 15.1.1.1 Business overview 387 15.1.1.2 Products offered 388 15.1.1.3 Recent developments 390 15.1.1.3.1 Product launches & approvals 390 15.1.1.3.2 Deals 391 15.1.1.4 MnM view 391 15.1.1.4.1 Key strengths 391 15.1.1.4.2 Strategic choices 391 15.1.1.4.3 Weaknesses and competitive threats 392 15.1.2 THERMO FISHER SCIENTIFIC 393 15.1.2.1 Business overview 393 15.1.2.2 Products offered 394 15.1.2.3 Recent developments 397 15.1.2.3.1 Product launches & approvals 397 15.1.2.3.2 Deals 397 15.1.2.4 MnM view 397 15.1.2.4.1 Key strengths 397 15.1.2.4.2 Strategic choices 398 15.1.2.4.3 Weaknesses & competitive threats 398 15.1.3 ILLUMINA, INC. 399 15.1.3.1 Business overview 399 15.1.3.2 Products & services offered 400 15.1.3.3 Recent developments 402 15.1.3.3.1 Product launches & approvals 402 15.1.3.3.2 Deals 402 15.1.3.4 MnM view 403 15.1.3.4.1 Key strengths 403 15.1.3.4.2 Strategic choices 403 15.1.3.4.3 Weaknesses and competitive threats 403   15.1.4 AGILENT TECHNOLOGIES, INC. 404 15.1.4.1 Business overview 404 15.1.4.2 Products & services offered 405 15.1.4.3 Recent developments 407 15.1.4.3.1 Product launches & approvals 407 15.1.4.3.2 Deals 408 15.1.4.4 MnM view 408 15.1.4.4.1 Key strengths 408 15.1.4.4.2 Strategic choices 408 15.1.4.4.3 Weaknesses and competitive threats 409 15.1.5 QIAGEN 410 15.1.5.1 Business overview 410 15.1.5.2 Products & services offered 411 15.1.5.3 Recent developments 412 15.1.5.3.1 Product launches & approvals 412 15.1.5.3.2 Deals 413 15.1.5.4 MnM view 413 15.1.5.4.1 Key strengths 413 15.1.5.4.2 Strategic choices 413 15.1.5.4.3 Weaknesses & competitive threats 414 15.1.6 BIO-RAD LABORATORIES, INC. 415 15.1.6.1 Business overview 415 15.1.6.2 Products & services offered 416 15.1.6.3 Recent developments 417 15.1.6.3.1 Deals 417 15.1.7 DANAHER CORPORATION 418 15.1.7.1 Business overview 418 15.1.7.2 Products offered 419 15.1.8 ABBOTT LABORATORIES 421 15.1.8.1 Business overview 421 15.1.8.2 Products offered 422 15.1.8.3 Recent developments 423 15.1.8.3.1 Deals 423 15.1.9 BIOMÉRIEUX 424 15.1.9.1 Business overview 424 15.1.9.2 Products & services offered 425 15.1.10 MERCK KGAA 426 15.1.10.1 Business overview 426 15.1.10.2 Products & services offered 427 15.1.10.3 Recent developments 428 15.1.10.3.1 Product launches & approvals 428   15.1.11 SIEMENS HEALTHINEERS AG 429 15.1.11.1 Business overview 429 15.1.11.2 Products offered 430 15.1.12 BECTON, DICKINSON AND COMPANY 432 15.1.12.1 Business overview 432 15.1.12.2 Products offered 433 15.2 OTHER PLAYERS 435 15.2.1 MYRIAD GENETICS 435 15.2.2 SYSMEX CORPORATION 436 15.2.3 HOLOGIC, INC. 437 15.2.4 QUEST DIAGNOSTICS 438 15.2.5 CENTOGENE N.V. 439 15.2.6 BIOGENEX 440 15.2.7 R&D SYSTEMS, INC. 441 15.2.8 BIOVISION INC. 442 15.2.9 OLINK 443 15.2.10 ASURAGEN, INC. 444 15.2.11 MESO SCALE DIAGNOSTICS, LLC 445 15.2.12 INVIVOSCRIBE, INC. 446 15.2.13 INOVIQ LTD. 447 15.2.14 NANTOMICS 448 16 RESEARCH METHODOLOGY 449 16.1 RESEARCH DATA 449 16.1.1 SECONDARY DATA 450 16.1.1.1 List of secondary sources 450 16.1.1.2 Key data from secondary sources 451 16.1.2 PRIMARY DATA 451 16.1.2.1 List of primary sources 452 16.1.2.2 Key data from primary sources 452 16.1.2.3 Key industry insights 453 16.1.2.4 Breakdown of primary interviews 454 16.2 MARKET SIZE ESTIMATION 454 16.2.1 TOTAL MARKET SIZE: CANCER BIOMARKERS MARKET 454 16.2.2 BOTTOM-UP APPROACH 454 16.2.2.1 Approach 1: Revenue estimation of key players 455 16.2.2.2 Approach 2: Study of annual reports and investor presentations 455 16.2.2.3 Approach 3: Primary interviews 455 16.2.2.4 Growth forecast 456 16.2.2.5 CAGR projections 456 16.2.3 TOP-DOWN APPROACH 457   16.3 DATA TRIANGULATION 458 16.4 RESEARCH ASSUMPTIONS 458 16.4.1 STUDY-RELATED ASSUMPTIONS 458 16.5 STUDY ASSUMPTIONS 459 16.5.1 PARAMETRIC ASSUMPTIONS 459 16.5.2 GROWTH RATE ASSUMPTIONS 460 16.6 RESEARCH LIMITATIONS 460 16.7 RISK ASSESSMENT 460 17 APPENDIX 461 17.1 DISCUSSION GUIDE 461 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 464 17.3 CUSTOMIZATION OPTIONS 466 17.4 RELATED REPORTS 466 17.5 AUTHOR DETAILS 467

TABLE 1 INCLUSIONS AND EXCLUSIONS 42 TABLE 2 ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+] ALL CANCERS 57 TABLE 3 CANCER INCIDENCE, BOTH SEXES, IN 2022 57 TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS 61 TABLE 5 IMPACT OF PORTER’S FIVE FORCES ON CANCER BIOMARKERS MARKET 73 TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 74 TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS 75 TABLE 8 EUROPE: MACROECONOMIC INDICATORS 76 TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS 76 TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS 76 TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 76 TABLE 12 CANCER BIOMARKERS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 81 TABLE 13 AVERAGE SELLING PRICE OF CANCER BIOMARKERS, BY KEY PLAYER, 2024–2026 (USD) 82 TABLE 14 AVERAGE SELLING PRICE OF CANCER BIOMARKERS PRODUCTS, BY REGION, 2024–2026 (USD) 82 TABLE 15 IMPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83 TABLE 16 EXPORT DATA FOR HS CODE 382200-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 83 TABLE 17 CANCER BIOMARKERS MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 84 TABLE 18 US-ADJUSTED RECIPROCAL TARIFF RATES 87 TABLE 19 KEY PATENTS IN CANCER BIOMARKERS MARKET, 2022–2026 96 TABLE 20 KEY COMPANIES IMPLEMENTING AI IN CANCER BIOMARKERS MARKET 99 TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 101 TABLE 22 KEY BUYING CRITERIA, BY PRODUCT 101 TABLE 23 ADOPTION BARRIERS & INTERNAL CHALLENGES 102 TABLE 24 CANCER BIOMARKERS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 103 TABLE 25 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 107 TABLE 26 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 108 TABLE 27 CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION) 108 TABLE 28 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 109 TABLE 29 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 109 TABLE 30 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 110 TABLE 31 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 110 TABLE 32 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 111 TABLE 33 CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024–2032 (USD MILLION) 112 TABLE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2032 (USD MILLION) 112 TABLE 35 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 113 TABLE 36 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 113 TABLE 37 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 114 TABLE 38 IMMUNOASSAYS MARKET, BY REGION, 2024–2032 (USD MILLION) 115 TABLE 39 MASS SPECTROMETRY MARKET, BY REGION, 2024–2032 (USD MILLION) 116 TABLE 40 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2024–2032 (USD MILLION) 117 TABLE 41 PROTEIN MICROARRAYS MARKET, BY REGION, 2024–2032 (USD MILLION) 118 TABLE 42 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2024–2032 (USD MILLION) 120 TABLE 43 CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 121 TABLE 44 CANCER BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2032 (USD MILLION) 121 TABLE 45 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2032 (USD MILLION) 122 TABLE 46 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2032 (USD MILLION) 122 TABLE 47 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 123 TABLE 48 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 123 TABLE 49 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2024–2032 (USD MILLION) 124 TABLE 50 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2024–2032 (USD MILLION) 125 TABLE 51 IN SITU HYBRIDIZATION MARKET, BY REGION, 2024–2032 (USD MILLION) 126 TABLE 52 CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION) 127 TABLE 53 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 127 TABLE 54 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 128 TABLE 55 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 128 TABLE 56 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER OMICS TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 129 TABLE 57 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 130 TABLE 58 CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2024–2032 (USD MILLION) 130 TABLE 59 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 131 TABLE 60 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 131 TABLE 61 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 132 TABLE 62 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY COUNTRY, 2024–2032 (USD MILLION) 132 TABLE 63 ULTRASOUND IMAGING MARKET, BY REGION, 2024–2032 (USD MILLION) 133 TABLE 64 NORTH AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 133 TABLE 65 EUROPE: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 134 TABLE 66 ASIA PACIFIC: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 134 TABLE 67 LATIN AMERICA: ULTRASOUND IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 135 TABLE 68 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION) 136 TABLE 69 NORTH AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 136 TABLE 70 EUROPE: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 137 TABLE 71 ASIA PACIFIC: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 137 TABLE 72 LATIN AMERICA: COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 138 TABLE 73 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2024–2032 (USD MILLION) 139 TABLE 74 NORTH AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 139 TABLE 75 EUROPE: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 140 TABLE 76 ASIA PACIFIC: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 140 TABLE 77 LATIN AMERICA: MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 141 TABLE 78 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION) 142 TABLE 79 NORTH AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 142 TABLE 80 EUROPE: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 143 TABLE 81 ASIA PACIFIC: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 143 TABLE 82 LATIN AMERICA: POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 144 TABLE 83 MAMMOGRAPHY MARKET, BY REGION, 2024–2032 (USD MILLION) 145 TABLE 84 NORTH AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 145 TABLE 85 EUROPE: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 146 TABLE 86 ASIA PACIFIC: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 146 TABLE 87 LATIN AMERICA: MAMMOGRAPHY MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 147 TABLE 88 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 149 TABLE 89 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040 151 TABLE 90 BREAST CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 151 TABLE 91 NORTH AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 151 TABLE 92 EUROPE: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 152 TABLE 93 ASIA PACIFIC: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 152 TABLE 94 LATIN AMERICA: BREAST CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 153 TABLE 95 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040 154 TABLE 96 LUNG CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 154 TABLE 97 NORTH AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 155 TABLE 98 EUROPE: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 155 TABLE 99 ASIA PACIFIC: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 156 TABLE 100 LATIN AMERICA: LUNG CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 156 TABLE 101 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040 157 TABLE 102 COLORECTAL CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 157 TABLE 103 NORTH AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 158 TABLE 104 EUROPE: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 158 TABLE 105 ASIA PACIFIC: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 159 TABLE 106 LATIN AMERICA: COLORECTAL CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 159 TABLE 107 PROSTATE CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 160 TABLE 108 NORTH AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 161 TABLE 109 EUROPE: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 161 TABLE 110 ASIA PACIFIC: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 162 TABLE 111 LATIN AMERICA: PROSTATE CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 162 TABLE 112 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040 163 TABLE 113 MELANOMA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 163 TABLE 114 NORTH AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 164 TABLE 115 EUROPE: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 164 TABLE 116 ASIA PACIFIC: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 165 TABLE 117 LATIN AMERICA: MELANOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 165 TABLE 118 LEUKEMIA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 166 TABLE 119 NORTH AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 166 TABLE 120 EUROPE: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 167 TABLE 121 ASIA PACIFIC: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 167 TABLE 122 LATIN AMERICA: LEUKEMIA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 168 TABLE 123 THYROID CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 169 TABLE 124 NORTH AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 169 TABLE 125 EUROPE: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 170 TABLE 126 ASIA PACIFIC: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 170 TABLE 127 LATIN AMERICA: THYROID CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 171 TABLE 128 BLADDER CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 172 TABLE 129 NORTH AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 172 TABLE 130 EUROPE: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 173 TABLE 131 ASIA PACIFIC: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 173 TABLE 132 LATIN AMERICA: BLADDER CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 174 TABLE 133 NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 175 TABLE 134 NORTH AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 175 TABLE 135 EUROPE: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 176 TABLE 136 ASIA PACIFIC: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 176 TABLE 137 LATIN AMERICA: NON-HODGKIN’S LYMPHOMA BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 177 TABLE 138 KIDNEY CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 178 TABLE 139 NORTH AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 178 TABLE 140 EUROPE: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 179 TABLE 141 ASIA PACIFIC: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 179 TABLE 142 LATIN AMERICA: KIDNEY CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 180 TABLE 143 OTHER CANCERS BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 181 TABLE 144 NORTH AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 181 TABLE 145 EUROPE: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 182 TABLE 146 ASIA PACIFIC: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 182 TABLE 147 LATIN AMERICA: OTHER CANCERS BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 183 TABLE 148 CANCER BIOMARKERS MARKET, BY PRODUCTS, 2024–2032 (USD MILLION) 185 TABLE 149 CANCER BIOMARKERS CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 186 TABLE 150 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2032 (USD MILLION) 186 TABLE 151 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 187 TABLE 152 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 187 TABLE 153 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 188 TABLE 154 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 188 TABLE 155 KITS & REAGENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 189 TABLE 156 NORTH AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 189 TABLE 157 EUROPE: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 190 TABLE 158 ASIA PACIFIC: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 190 TABLE 159 LATIN AMERICA: KITS & REAGENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 191 TABLE 160 ANTIBODIES MARKET, BY REGION, 2024–2032 (USD MILLION) 192 TABLE 161 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 192 TABLE 162 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 193 TABLE 163 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 193 TABLE 164 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 194 TABLE 165 PROBES MARKET, BY REGION, 2024–2032 (USD MILLION) 194 TABLE 166 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 195 TABLE 167 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 195 TABLE 168 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 196 TABLE 169 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 196 TABLE 170 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 197 TABLE 171 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 197 TABLE 172 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 198 TABLE 173 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 198 TABLE 174 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 199 TABLE 175 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 199 TABLE 176 IMAGING INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 200 TABLE 177 NORTH AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 201 TABLE 178 EUROPE: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 201 TABLE 179 ASIA PACIFIC: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 202 TABLE 180 LATIN AMERICA: IMAGING INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 202 TABLE 181 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 203 TABLE 182 NORTH AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 203 TABLE 183 EUROPE: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 204 TABLE 184 ASIA PACIFIC: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 204 TABLE 185 LATIN AMERICA: PATHOLOGY-BASED INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 205 TABLE 186 BIOPSY INSTRUMENTS MARKET, BY REGION, 2024–2032 (USD MILLION) 205 TABLE 187 NORTH AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 206 TABLE 188 EUROPE: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 206 TABLE 189 ASIA PACIFIC: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 207 TABLE 190 LATIN AMERICA: BIOPSY INSTRUMENTS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 207 TABLE 191 BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2024–2032 (USD MILLION) 208 TABLE 192 NORTH AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 209 TABLE 193 EUROPE: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 209 TABLE 194 ASIA PACIFIC: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 210 TABLE 195 LATIN AMERICA: BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 210 TABLE 196 CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 212 TABLE 197 CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY REGION, 2024–2032 (USD MILLION) 213 TABLE 198 NORTH AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 213 TABLE 199 EUROPE: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 214 TABLE 200 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 214 TABLE 201 LATIN AMERICA: CANCER BIOMARKERS MARKET IN DIAGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 215 TABLE 202 CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY REGION, 2024–2032 (USD MILLION) 216 TABLE 203 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION) 216 TABLE 204 EUROPE: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION) 217 TABLE 205 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION) 217 TABLE 206 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RESEARCH & DEVELOPMENT, BY COUNTRY, 2024–2032 (USD MILLION) 218 TABLE 207 CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY REGION, 2024–2032 (USD MILLION) 219 TABLE 208 NORTH AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 219 TABLE 209 EUROPE: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 220 TABLE 210 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 220 TABLE 211 LATIN AMERICA: CANCER BIOMARKERS MARKET IN PROGNOSTICS, BY COUNTRY, 2024–2032 (USD MILLION) 221 TABLE 212 CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY REGION, 2024–2032 (USD MILLION) 222 TABLE 213 NORTH AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION) 222 TABLE 214 EUROPE: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION) 223 TABLE 215 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION) 223 TABLE 216 LATIN AMERICA: CANCER BIOMARKERS MARKET IN RISK ASSESSMENT, BY COUNTRY, 2024–2032 (USD MILLION) 224 TABLE 217 CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY REGION, 2024–2032 (USD MILLION) 225 TABLE 218 NORTH AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION) 225 TABLE 219 EUROPE: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION) 226 TABLE 220 ASIA PACIFIC: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION) 226 TABLE 221 LATIN AMERICA: CANCER BIOMARKERS MARKET IN OTHER APPLICATIONS, BY COUNTRY, 2024–2032 (USD MILLION) 227 TABLE 222 CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 229 TABLE 223 CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024–2032 (USD MILLION) 230 TABLE 224 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION) 231 TABLE 225 EUROPE: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION) 231 TABLE 226 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION) 232 TABLE 227 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2032 (USD MILLION) 232 TABLE 228 CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2024–2032 (USD MILLION) 233 TABLE 229 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 234 TABLE 230 EUROPE: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 234 TABLE 231 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 235 TABLE 232 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2024–2032 (USD MILLION) 235 TABLE 233 CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2024–2032 (USD MILLION) 236 TABLE 234 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 237 TABLE 235 EUROPE: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 237 TABLE 236 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 238 TABLE 237 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY COUNTRY, 2024–2032 (USD MILLION) 238 TABLE 238 CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024–2032 (USD MILLION) 239 TABLE 239 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION) 240 TABLE 240 EUROPE: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION) 240 TABLE 241 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION) 241 TABLE 242 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2032 (USD MILLION) 241 TABLE 243 CANCER BIOMARKERS MARKET, BY REGION, 2024–2032 (USD MILLION) 243 TABLE 244 NORTH AMERICA: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 244 TABLE 245 NORTH AMERICA: MACROECONOMIC INDICATORS 245 TABLE 246 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 246 TABLE 247 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 246 TABLE 248 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 246 TABLE 249 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 247 TABLE 250 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 247 TABLE 251 NORTH AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 248 TABLE 252 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 248 TABLE 253 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 249 TABLE 254 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 249 TABLE 255 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 249 TABLE 256 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 250 TABLE 257 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 250 TABLE 258 US - NUMBER OF CANCER BIOMARKER TESTS FOR NON-SMALL CELL LUNG CANCER, BY SAMPLE TYPE, 2024–2032 (TESTS) 252 TABLE 259 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 252 TABLE 260 US: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 253 TABLE 261 US: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 253 TABLE 262 US: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 254 TABLE 263 US: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 254 TABLE 264 US: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 255 TABLE 265 US: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 255 TABLE 266 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 256 TABLE 267 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 256 TABLE 268 US: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 256 TABLE 269 US: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 257 TABLE 270 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 258 TABLE 271 CANADA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 259 TABLE 272 CANADA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 259 TABLE 273 CANADA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 260 TABLE 274 CANADA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 260 TABLE 275 CANADA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 261 TABLE 276 CANADA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 261 TABLE 277 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 262 TABLE 278 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 262 TABLE 279 CANADA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 263 TABLE 280 CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 263 TABLE 281 EUROPE: ESTIMATED NUMBER OF NEW CASES FROM 2022 TO 2045, INCIDENCE, BOTH SEXES, AGE [0-85+], BY CANCER TYPE 265 TABLE 282 MACROECONOMIC INDICATORS FOR EUROPE 265 TABLE 283 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 266 TABLE 284 EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 266 TABLE 285 EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 267 TABLE 286 EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 267 TABLE 287 EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 268 TABLE 288 EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 268 TABLE 289 EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 269 TABLE 290 EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 269 TABLE 291 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 270 TABLE 292 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 270 TABLE 293 EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 271 TABLE 294 EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 271 TABLE 295 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 273 TABLE 296 GERMANY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 273 TABLE 297 GERMANY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 274 TABLE 298 GERMANY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 274 TABLE 299 GERMANY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 275 TABLE 300 GERMANY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 275 TABLE 301 GERMANY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 276 TABLE 302 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 276 TABLE 303 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 276 TABLE 304 GERMANY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 277 TABLE 305 GERMANY: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 277 TABLE 306 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 278 TABLE 307 UK: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 279 TABLE 308 UK: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 279 TABLE 309 UK: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 280 TABLE 310 UK: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 280 TABLE 311 UK: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 281 TABLE 312 UK: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 281 TABLE 313 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 282 TABLE 314 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 282 TABLE 315 UK: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 282 TABLE 316 UK: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 283 TABLE 317 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 284 TABLE 318 FRANCE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 284 TABLE 319 FRANCE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 284 TABLE 320 FRANCE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 285 TABLE 321 FRANCE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 285 TABLE 322 FRANCE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 286 TABLE 323 FRANCE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 286 TABLE 324 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 287 TABLE 325 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 287 TABLE 326 FRANCE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 288 TABLE 327 FRANCE: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 288 TABLE 328 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 289 TABLE 329 ITALY: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 289 TABLE 330 ITALY: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 290 TABLE 331 ITALY: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 290 TABLE 332 ITALY: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 291 TABLE 333 ITALY: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 291 TABLE 334 ITALY: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 292 TABLE 335 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 292 TABLE 336 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 292 TABLE 337 ITALY: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 293 TABLE 338 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 293 TABLE 339 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 294 TABLE 340 SPAIN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 294 TABLE 341 SPAIN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 295 TABLE 342 SPAIN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 295 TABLE 343 SPAIN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 296 TABLE 344 SPAIN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 296 TABLE 345 SPAIN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 297 TABLE 346 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 297 TABLE 347 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 297 TABLE 348 SPAIN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 298 TABLE 349 SPAIN: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 298 TABLE 350 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 299 TABLE 351 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 299 TABLE 352 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 300 TABLE 353 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 300 TABLE 354 REST OF EUROPE: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 301 TABLE 355 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 301 TABLE 356 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 302 TABLE 357 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 302 TABLE 358 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 302 TABLE 359 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 303 TABLE 360 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 303 TABLE 361 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 305 TABLE 362 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 306 TABLE 363 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 306 TABLE 364 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 306 TABLE 365 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 307 TABLE 366 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 307 TABLE 367 ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 308 TABLE 368 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 308 TABLE 369 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 309 TABLE 370 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 309 TABLE 371 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 309 TABLE 372 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 310 TABLE 373 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 310 TABLE 374 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 311 TABLE 375 CHINA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 312 TABLE 376 CHINA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 312 TABLE 377 CHINA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 313 TABLE 378 CHINA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 313 TABLE 379 CHINA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 314 TABLE 380 CHINA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 314 TABLE 381 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 315 TABLE 382 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 315 TABLE 383 CHINA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 315 TABLE 384 CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 316 TABLE 385 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 317 TABLE 386 JAPAN: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 317 TABLE 387 JAPAN: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 317 TABLE 388 JAPAN: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 318 TABLE 389 JAPAN: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 318 TABLE 390 JAPAN: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 319 TABLE 391 JAPAN: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 319 TABLE 392 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 320 TABLE 393 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 320 TABLE 394 JAPAN: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 320 TABLE 395 JAPAN: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 321 TABLE 396 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 322 TABLE 397 INDIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 322 TABLE 398 INDIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 323 TABLE 399 INDIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 323 TABLE 400 INDIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 324 TABLE 401 INDIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 324 TABLE 402 INDIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 325 TABLE 403 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 325 TABLE 404 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 325 TABLE 405 INDIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 326 TABLE 406 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 326 TABLE 407 AUSTRALIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 327 TABLE 408 AUSTRALIA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 327 TABLE 409 AUSTRALIA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 328 TABLE 410 AUSTRALIA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 328 TABLE 411 AUSTRALIA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 329 TABLE 412 AUSTRALIA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 329 TABLE 413 AUSTRALIA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 330 TABLE 414 AUSTRALIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 330 TABLE 415 AUSTRALIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 330 TABLE 416 AUSTRALIA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 331 TABLE 417 AUSTRALIA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 331 TABLE 418 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 332 TABLE 419 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 332 TABLE 420 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 333 TABLE 421 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 333 TABLE 422 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 334 TABLE 423 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 334 TABLE 424 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 335 TABLE 425 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 335 TABLE 426 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 335 TABLE 427 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 336 TABLE 428 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 336 TABLE 429 MACROECONOMIC INDICATORS FOR LATIN AMERICA 337 TABLE 430 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2024–2032 (USD MILLION) 338 TABLE 431 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 338 TABLE 432 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 338 TABLE 433 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 339 TABLE 434 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 339 TABLE 435 LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 340 TABLE 436 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 340 TABLE 437 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 341 TABLE 438 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 341 TABLE 439 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 341 TABLE 440 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 342 TABLE 441 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 342 TABLE 442 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 343 TABLE 443 BRAZIL: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 343 TABLE 444 BRAZIL: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 344 TABLE 445 BRAZIL: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 344 TABLE 446 BRAZIL: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 345 TABLE 447 BRAZIL: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 345 TABLE 448 BRAZIL: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 346 TABLE 449 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 346 TABLE 450 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 346 TABLE 451 BRAZIL: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 347 TABLE 452 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 347 TABLE 453 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 348 TABLE 454 MEXICO: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 348 TABLE 455 MEXICO: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 349 TABLE 456 MEXICO: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 349 TABLE 457 MEXICO: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 350 TABLE 458 MEXICO: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 350 TABLE 459 MEXICO: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 351 TABLE 460 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 351 TABLE 461 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 351 TABLE 462 MEXICO: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 352 TABLE 463 MEXICO: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 352 TABLE 464 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 353 TABLE 465 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 353 TABLE 466 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 354 TABLE 467 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 354 TABLE 468 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 355 TABLE 469 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 355 TABLE 470 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 356 TABLE 471 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 356 TABLE 472 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 356 TABLE 473 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 357 TABLE 474 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 357 TABLE 475 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 358 TABLE 476 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 359 TABLE 477 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 359 TABLE 478 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 360 TABLE 479 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 360 TABLE 480 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 361 TABLE 481 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 361 TABLE 482 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 362 TABLE 483 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 362 TABLE 484 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 362 TABLE 485 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 363 TABLE 486 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024–2032 (USD MILLION) 364 TABLE 487 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 364 TABLE 488 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR PROTEOMICS, BY TYPE, 2024–2032 (USD MILLION) 365 TABLE 489 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR GENOMICS, BY TYPE, 2024–2032 (USD MILLION) 365 TABLE 490 GCC COUNTRIES: CANCER BIOMARKERS MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2024–2032 (USD MILLION) 366 TABLE 491 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2024–2032 (USD MILLION) 366 TABLE 492 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY PRODUCT, 2024–2032 (USD MILLION) 367 TABLE 493 GCC COUNTRIES: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2024–2032 (USD MILLION) 367 TABLE 494 GCC COUNTRIES: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2032 (USD MILLION) 367 TABLE 495 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY APPLICATION, 2024–2032 (USD MILLION) 368 TABLE 496 GCC COUNTRIES: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032 (USD MILLION) 368 TABLE 497 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN CANCER BIOMARKERS MARKET, JANUARY 2023−APRIL 2026 369 TABLE 498 CANCER BIOMARKERS MARKET: DEGREE OF COMPETITION 372 TABLE 499 CANCER BIOMARKER MARKET: REGIONAL FOOTPRINT, 2025 377 TABLE 500 CANCER BIOMARKER MARKET: PRODUCT FOOTPRINT, 2025 378 TABLE 501 CANCER BIOMARKER MARKET: PROFILING TECHNOLOGY FOOTPRINT, 2025 379 TABLE 502 CANCER BIOMARKER MARKET: APPLICATION FOOTPRINT, 2025 379 TABLE 503 CANCER BIOMARKER MARKET: DETAILED LIST OF KEY STARTUPS/SMES, 2025 382 TABLE 504 CANCER BIOMARKER MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2), 2025 382 TABLE 505 CANCER BIOMARKER MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2), 2025 383 TABLE 506 CANCER BIOMARKER MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 385 TABLE 507 CANCER BIOMARKER MARKET: DEALS, JANUARY 2023–APRIL 2026 386 TABLE 508 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 387 TABLE 509 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED 388 TABLE 510 F. HOFFMANN-LA ROCHE AG: PRODUCT LAUNCHES & APPROVALS 390 TABLE 511 F. HOFFMANN-LA ROCHE AG: DEALS 391 TABLE 512 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 393 TABLE 513 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 394 TABLE 514 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS 397 TABLE 515 THERMO FISHER SCIENTIFIC INC.: DEALS 397 TABLE 516 ILLUMINA, INC.: COMPANY OVERVIEW 399 TABLE 517 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED 400 TABLE 518 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS 402 TABLE 519 ILLUMINA, INC.: DEALS 402 TABLE 520 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 404 TABLE 521 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 405 TABLE 522 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS 407 TABLE 523 AGILENT TECHNOLOGIES, INC.: DEALS 408 TABLE 524 QIAGEN: COMPANY OVERVIEW 410 TABLE 525 QIAGEN: PRODUCTS & SERVICES OFFERED 411 TABLE 526 QIAGEN: PRODUCT LAUNCHES & APPROVALS 412 TABLE 527 QIAGEN: DEALS 413 TABLE 528 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 415 TABLE 529 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 416 TABLE 530 BIO-RAD LABORATORIES, INC.: DEALS 417 TABLE 531 DANAHER CORPORATION: COMPANY OVERVIEW 418 TABLE 532 DANAHER CORPORATION: PRODUCTS OFFERED 419 TABLE 533 ABBOTT LABORATORIES: COMPANY OVERVIEW 421 TABLE 534 ABBOTT LABORATORIES: PRODUCTS OFFERED 422 TABLE 535 ABBOTT LABORATORIES: DEALS 423 TABLE 536 BIOMÉRIEUX: COMPANY OVERVIEW 424 TABLE 537 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED 425 TABLE 538 MERCK KGAA: BUSINESS OVERVIEW 426 TABLE 539 MERCK KGAA: PRODUCTS & SERVICES OFFERED 427 TABLE 540 MERCK KGAA: PRODUCT LAUNCHES & APPROVALS 428 TABLE 541 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 429 TABLE 542 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 430 TABLE 543 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 432 TABLE 544 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 433 TABLE 545 MYRIAD GENETICS: COMPANY OVERVIEW 435 TABLE 546 SYSMEX CORPORATION: COMPANY OVERVIEW 436 TABLE 547 HOLOGIC, INC.: COMPANY OVERVIEW 437 TABLE 548 QUEST DIAGNOSTICS: COMPANY OVERVIEW 438 TABLE 549 CENTOGENE N.V.: COMPANY OVERVIEW 439 TABLE 550 BIOGENEX: COMPANY OVERVIEW 440 TABLE 551 R&D SYSTEMS, INC.: COMPANY OVERVIEW 441 TABLE 552 BIOVISION INC.: COMPANY OVERVIEW 442 TABLE 553 OLINK: COMPANY OVERVIEW 443 TABLE 554 ASURAGEN, INC.: COMPANY OVERVIEW 444 TABLE 555 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW 445 TABLE 556 INVIVOSCRIBE, INC.: COMPANY OVERVIEW 446 TABLE 557 INOVIQ LTD.: COMPANY OVERVIEW 447 TABLE 558 NANTOMICS: COMPANY OVERVIEW 448 TABLE 559 KEY DATA FROM PRIMARY SOURCES 452 TABLE 560 CANCER BIOMARKERS MARKET: RISK ASSESSMENT 460 FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION 41 FIGURE 2 STUDY YEARS CONSIDERED 43 FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 45 FIGURE 4 GLOBAL CANCER BIOMARKERS MARKET, 2024–2031 46 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023–2026 46 FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER BIOMARKERS MARKET 47 FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN CANCER BIOMARKERS MARKET, 2025 48 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49 FIGURE 9 RISING PREVALENCE OF CANCER TO DRIVE MARKET 50 FIGURE 10 OMICS TECHNOLOGIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51 FIGURE 11 BREAST CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51 FIGURE 12 CONSUMABLES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 13 DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 14 DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST SHARE DURING FORECAST PERIOD 53 FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53 FIGURE 16 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55 FIGURE 17 CANCER BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS 72 FIGURE 18 CANCER BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 78 FIGURE 19 CANCER BIOMARKERS MARKET: VALUE CHAIN ANALYSIS 79 FIGURE 20 CANCER BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 80 FIGURE 21 CANCER BIOMARKERS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 85 FIGURE 22 NUMBER OF DEALS & FUNDING ACTIVITIES IN CANCER BIOMARKERS MARKET 86 FIGURE 23 PATENT ANALYSIS FOR CANCER BIOMARKERS, JANUARY 2016–DECEMBER 2025 95 FIGURE 24 MARKET POTENTIAL OF AI IN CANCER BIOMARKERS MARKET 98 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 100 FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT 101 FIGURE 27 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT 245 FIGURE 28 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT 305 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS MARKET, 2023–2025 (USD MILLION) 371 FIGURE 30 GLOBAL CANCER BIOMARKERS MARKET SHARE ANALYSIS, 2025 372 FIGURE 31 US: CANCER BIOMARKER MARKET SHARE ANALYSIS, 2025 374 FIGURE 32 CANCER BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 376 FIGURE 33 CANCER BIOMARKERS MARKET: COMPANY FOOTPRINT, 2025 377 FIGURE 34 CANCER BIOMARKER MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 381 FIGURE 35 EV/EBITDA OF KEY VENDORS, 2026 383 FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2026 384 FIGURE 37 CANCER BIOMARKER MARKET: BRAND/PRODUCT COMPARISON FOR CANCER BIOMARKER 384 FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2025) 388 FIGURE 39 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT, 2025 394 FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT, 2025 399 FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2025 405 FIGURE 42 QIAGEN: COMPANY SNAPSHOT, 2025 411 FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT, 2025 416 FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 419 FIGURE 45 ABBOTT LABORATORIES: COMPANY SNAPSHOT, 2025 422 FIGURE 46 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 425 FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT, 2025 427 FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025 430 FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT, 2025 433 FIGURE 50 RESEARCH DESIGN 449 FIGURE 51 KEY DATA FROM SECONDARY SOURCES 451 FIGURE 52 LIST OF PRIMARY SOURCES 452 FIGURE 53 KEY INDUSTRY INSIGHTS 453 FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION 454 FIGURE 55 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS 455 FIGURE 56 CAGR PROJECTIONS 456 FIGURE 57 TOP-DOWN APPROACH 457 FIGURE 58 DATA TRIANGULATION 458 FIGURE 59 PARAMETRIC ASSUMPTIONS 459